Ueda T, Araki N, Mano M, Myoui A, Joyama S, Ishiguro S, Yamamura H, Takahashi K, Kudawara I, Yoshikawa H
Department of Orthopaedic Surgery, Osaka University Graduate School of Medicine, 2-2 Yamada-oka, Suita, Osaka 565-0871, Japan.
J Clin Pathol. 2002 Nov;55(11):853-8. doi: 10.1136/jcp.55.11.853.
BACKGROUND/AIMS: Malignant fibrous histiocytoma (MFH) of bone, a relatively rare primary malignant bone tumour, is a distinct clinicopathological entity as opposed to MFH derived from soft tissue. Although the true histogenesis of this condition is still controversial, a considerable number of cases of MFH in soft tissue show positive immunohistochemical reactivity for muscle markers such as desmin, common muscle actin (HHF35), and alpha smooth muscle actin (SMA), suggesting that MFH cells are myofibroblastic in nature.
This study investigated immunoreactivity for several different muscle markers in 19 cases of MFH of bone together with reverse transcription polymerase chain reaction (RT-PCR) analysis on frozen tissue samples that were available in four cases, and compared the data with those found in 11 cases of osteosarcoma and 11 cases of soft tissue MFH treated over the same period.
Immunohistochemistry revealed that MFH of bone showed relatively frequent expression of smooth muscle markers, including calponin (nine cases), alpha-SMA (nine cases), and SM22alpha (18 cases), and this was confirmed by RT-PCR analysis. However, only one, two, and three cases of MFH of bone showed positive staining for desmin, MyoD1, and HHF35, respectively. Similarly, 11 osteosarcoma cases were relatively frequently positive for alpha-SMA (five cases), calponin (four cases), and SM22alpha (seven cases), and less frequently positive for desmin (one case), MyoD1 (none), and HHF35 (none). In contrast, very few MFH of soft tissue cases (n = 11) showed positive reactivity for all of these muscle markers. It has recently been reported that human bone marrow stromal cells also express various kinds of smooth muscle markers including alpha-SMA and calponin.
These results suggested that MFH of bone may derive from mesenchymal stromal cells in bone marrow and has a more myofibroblastic differentiation than soft tissue MFH.
背景/目的:骨恶性纤维组织细胞瘤(MFH)是一种相对罕见的原发性恶性骨肿瘤,与软组织来源的MFH是不同的临床病理实体。尽管这种疾病的真正组织发生仍存在争议,但相当数量的软组织MFH病例对肌肉标志物如结蛋白、普通肌动蛋白(HHF35)和α平滑肌肌动蛋白(SMA)表现出免疫组化阳性反应,提示MFH细胞本质上是肌成纤维细胞。
本研究调查了19例骨MFH对几种不同肌肉标志物的免疫反应性,并对4例可获得的冰冻组织样本进行逆转录聚合酶链反应(RT-PCR)分析,同时将数据与同期治疗的11例骨肉瘤和11例软组织MFH的结果进行比较。
免疫组化显示,骨MFH相对频繁地表达平滑肌标志物,包括钙调蛋白(9例)、α-SMA(9例)和SM22α(18例),RT-PCR分析证实了这一点。然而,骨MFH分别只有1例、2例和3例对结蛋白、MyoD1和HHF35呈阳性染色。同样,11例骨肉瘤病例中,α-SMA(5例)、钙调蛋白(4例)和SM22α(7例)相对频繁呈阳性,而结蛋白(1例)、MyoD1(无)和HHF35(无)呈阳性的频率较低。相比之下,很少有软组织MFH病例(n = 11)对所有这些肌肉标志物呈阳性反应。最近有报道称,人骨髓基质细胞也表达包括α-SMA和钙调蛋白在内的多种平滑肌标志物。
这些结果提示,骨MFH可能起源于骨髓间充质基质细胞,并且比软组织MFH具有更多的肌成纤维细胞分化。